rpl-23 Antibody

What is RPL23 and what cellular functions does it serve?

RPL23 (Ribosomal Protein L23) is a component of the 60S ribosomal subunit essential for protein synthesis. Beyond its canonical role in translation, RPL23 functions in nucleolar stress response pathways, p53 regulation, and cell cycle control. In research contexts, RPL23 has been implicated in cancer progression, immune response modulation, and epigenetic mechanisms . Methodologically, researchers typically use RPL23 antibodies in conjunction with other ribosomal markers to investigate translation regulation in cellular stress conditions, with immunoprecipitation techniques revealing its interactions with non-ribosomal proteins.

What applications are RPL23 antibodies typically used for?

RPL23 antibodies are employed across multiple experimental techniques including immunocytochemistry (ICC), immunofluorescence (IF), immunohistochemistry on paraffin-embedded tissues (IHC-P), and Western blotting (WB) . For optimal results in ICC/IF applications, researchers should use 1:100-1:500 dilutions with paraformaldehyde fixation and Triton X-100 permeabilization. For IHC-P, antigen retrieval using citrate buffer (pH 6.0) improves signal detection, while Western blotting typically employs 1:1000-1:5000 dilutions with detection of a ~15 kDa band representing RPL23.

What are the specifications of commercially available RPL23 antibodies?

Commercial RPL23 antibodies are typically rabbit-derived polyclonal antibodies (pAb) with IgG isotype characteristics. These antibodies are generated using immunogens containing recombinant fusion proteins with amino acid sequences 1-140 of human RPL23 (NP_000969.1) . Most preparations are formulated in PBS with 0.02% sodium azide and 50% glycerol for stability. Cross-reactivity typically includes human, mouse, and rat samples, making these antibodies versatile for comparative studies across mammalian models.

How should I design validation experiments for a new RPL23 antibody?

A comprehensive validation protocol for RPL23 antibodies should include:

• Specificity testing: Western blot analysis comparing wildtype versus RPL23 knockdown samples

• Cross-reactivity assessment: Parallel testing across human, mouse, and rat samples

• Application-specific validation: For each intended application (ICC, IF, IHC, WB), perform:

  • Titration series (1:50 to 1:5000) to determine optimal concentration

  • Positive and negative control tissues/cell lines

  • Competing peptide blocking tests to confirm specificity

• Reproducibility testing: Independent experiments by different operators

Documentation should include representative images of all validation experiments with quantification of signal-to-noise ratios.

What controls should be included when using RPL23 antibodies?

When employing RPL23 antibodies, researchers should implement the following controls:

Implementing these controls enables researchers to confidently interpret RPL23 antibody staining patterns and distinguish between specific and non-specific signals.

How do fixation and sample preparation methods affect RPL23 antibody performance?

Fixation conditions significantly impact RPL23 antibody performance. For optimal results:

• ICC/IF applications: 4% paraformaldehyde for 15 minutes at room temperature preserves epitope accessibility while maintaining cellular architecture. Overfixation with glutaraldehyde may mask the epitope.

• IHC applications: Formalin-fixed paraffin-embedded (FFPE) tissues require heat-induced epitope retrieval (HIER) using citrate buffer (pH 6.0) for 15-20 minutes. Protease-based antigen retrieval methods often degrade the epitope.

• Western blotting: Sample preparation with RIPA buffer containing protease inhibitors yields optimal results. Heat denaturation should not exceed 95°C for 5 minutes to prevent epitope destruction.

• Storage considerations: Prepared samples should be analyzed within 24-48 hours, as prolonged storage can reduce antibody binding efficiency.

How can RPL23 antibodies be used to investigate extraribosomal functions?

Recent research indicates RPL23 performs significant functions beyond its structural role in ribosomes. To investigate these extraribosomal functions:

• Nucleolar stress response: Use RPL23 antibodies in conjunction with actinomycin D treatment to track nucleolar-to-nucleoplasmic translocation via immunofluorescence time-course experiments.

• p53 pathway interaction: Implement co-immunoprecipitation with RPL23 antibodies followed by immunoblotting for MDM2 and p53 to investigate regulatory interactions.

• Cell cycle regulation: Combine RPL23 immunostaining with EdU incorporation or cyclin markers to correlate expression patterns with specific cell cycle phases.

• Cellular compartment fractionation: Use subcellular fractionation followed by Western blotting with RPL23 antibodies to quantify distribution between ribosomal and non-ribosomal pools.

These approaches require careful validation of antibody specificity in each subcellular compartment, as epitope accessibility may vary based on RPL23's interaction partners.

What approaches can resolve contradictory findings when using different RPL23 antibodies?

When confronted with conflicting results using different RPL23 antibodies, implement this systematic troubleshooting approach:

• Epitope mapping: Determine the precise epitope recognition region for each antibody and assess potential masking in different experimental contexts.

• Post-translational modification sensitivity: Test whether phosphorylation, ubiquitination, or other modifications affect antibody binding using phosphatase treatment or modification-specific antibodies.

• Cross-validation with orthogonal methods:

  • Complement antibody-based detection with mRNA expression analysis

  • Validate with tagged RPL23 constructs detected via tag-specific antibodies

  • Implement mass spectrometry-based protein identification

• Knockout/knockdown validation: Generate RPL23-depleted samples as definitive negative controls to confirm specificity of each antibody.

A comprehensive approach involves creating a validation matrix documenting performance of each antibody across multiple techniques, fixation conditions, and cell types.

How can RPL23 antibodies be employed in cancer research applications?

RPL23 has emerging roles in cancer biology, making its antibodies valuable for oncology research . Advanced applications include:

• Tumor biomarker evaluation: Analyze RPL23 expression patterns across tumor microarrays using standardized IHC protocols with quantitative scoring systems like H-score or Allred.

• Therapy response monitoring: Track changes in RPL23 expression or localization following treatment with ribosomal biosynthesis inhibitors or nucleolar stress inducers.

• Cancer stem cell identification: Combine RPL23 antibodies with cancer stem cell markers in multicolor flow cytometry to identify populations with altered ribosomal biogenesis.

• Ribosome heterogeneity analysis: Use RPL23 antibodies in combination with other ribosomal protein markers to assess compositional changes in cancer-associated ribosomes.

These applications require careful optimization of multiplexed detection systems and quantitative image analysis algorithms for accurate interpretation.

What strategies can address non-specific background when using RPL23 antibodies?

Non-specific background is a common challenge with RPL23 antibodies that can be mitigated through these methodological refinements:

• Blocking optimization:

  • Test different blocking agents (5% BSA, 5% normal serum, commercial blockers)

  • Extend blocking time to 2-3 hours at room temperature

  • Include 0.1-0.3% Triton X-100 in blocking buffer for better penetration

• Antibody dilution optimization:

  • Perform sequential dilutions from 1:100 to 1:2000

  • Incubate at 4°C overnight rather than at room temperature

  • Consider using signal amplification systems for higher dilutions

• Washing protocol refinement:

  • Increase wash steps to 5-6 times

  • Extend wash duration to 10 minutes per wash

  • Add 0.05% Tween-20 to wash buffers

• Sample-specific adjustments:

  • For tissues with high endogenous biotin, use avidin/biotin blocking kits

  • For highly autofluorescent samples, include Sudan Black B treatment

Implementing these strategies systematically while maintaining control experiments will help establish optimal signal-to-noise ratios.

How can I optimize RPL23 antibody performance in dual immunofluorescence experiments?

For successful dual immunofluorescence experiments with RPL23 antibodies:

• Sequential staining protocol:

  • Apply RPL23 antibody first, complete detection with fluorophore-conjugated secondary

  • Block remaining rabbit IgG binding sites with excess unconjugated anti-rabbit Fab fragments

  • Apply second primary antibody (from different host species), followed by differently-labeled secondary antibody

• Fluorophore selection considerations:

  • Choose spectrally distinct fluorophores (e.g., Alexa 488 and Alexa 647)

  • Account for RPL23's abundant expression when selecting fluorophore brightness

  • Consider RPL23's nucleolar localization when selecting other markers to avoid spatial overlap

• Controls for dual staining:

  • Single-stained controls to assess bleed-through

  • Secondary-only controls to detect non-specific binding

  • Absorption controls with competing peptides

• Image acquisition parameters:

  • Sequential scanning rather than simultaneous detection

  • Narrow bandpass filter settings to minimize spectral overlap

  • Consistent exposure settings across experimental groups

These approaches minimize cross-reactivity issues while maintaining detection sensitivity for both targets.

How can RPL23 antibodies be adapted for use in super-resolution microscopy?

Adapting RPL23 antibodies for super-resolution microscopy requires specific modifications:

• Antibody fragmentation:

  • Convert to Fab fragments to reduce the ~15nm size of intact IgG

  • Use directly labeled primary antibodies to eliminate secondary antibody displacement error

• Fluorophore selection:

  • For STORM/PALM: Use photo-switchable dyes (Alexa 647, Atto 488)

  • For STED: Select dyes with good depletion properties (STAR 580, STAR RED)

  • For SIM: Choose bright, photostable fluorophores (Alexa 488, Janelia Fluor dyes)

• Sample preparation refinements:

  • Use thinner sections (70-100nm for best results)

  • Implement expansion microscopy protocols for improved resolution

  • Consider embedding in specialized mounting media with matched refractive index

• Validation approaches:

  • Correlate super-resolution images with electron microscopy

  • Compare with conventional confocal microscopy for consistency

  • Perform quantitative analysis of feature sizes to confirm resolution improvement

These adaptations enable nanoscale visualization of RPL23 distribution and interactions within subcellular compartments.

How can RPL23 antibodies contribute to understanding ribosome heterogeneity?

Emerging research on ribosome heterogeneity can leverage RPL23 antibodies through these approaches:

• Specialized ribosomes identification:

  • Combine RPL23 antibodies with other ribosomal protein markers in multiplexed IF

  • Implement proximity ligation assays to detect specific ribosomal protein combinations

  • Use RPL23 antibodies in polysome profiling followed by Western blotting

• Tissue-specific expression patterns:

  • Apply RPL23 antibodies across tissue microarrays to map expression variations

  • Combine with cell-type-specific markers for co-localization analysis

  • Quantify nucleolar vs. cytoplasmic distribution ratios across cell types

• Developmental regulation:

  • Track RPL23 expression patterns during embryogenesis and differentiation

  • Correlate with translation rates using puromycin incorporation assays

  • Analyze post-translational modifications affecting ribosome composition

These applications require careful quantitative image analysis and combination with functional translation assays to establish biological significance.

What considerations apply when using RPL23 antibodies in immunoprecipitation for ribosome interaction studies?

When using RPL23 antibodies for immunoprecipitation to study ribosome interactions:

• Lysis buffer optimization:

  • For intact ribosome isolation: Use gentle lysis buffers containing 100mM KCl, 5mM MgCl₂

  • For specific interaction partners: Use RIPA buffer supplemented with RNase inhibitors

  • Consider crosslinking with formaldehyde to preserve transient interactions

• Immunoprecipitation strategy:

  • Pre-clear lysates extensively to reduce non-specific binding

  • Use magnetic beads rather than agarose for gentler handling

  • Include RNase inhibitors to preserve RNA-dependent interactions

  • Consider tandem affinity purification for higher purity

• Controls and validation:

  • Include IgG control immunoprecipitations

  • Perform reverse immunoprecipitation with suspected interaction partners

  • Validate interactions with proximity ligation assays in intact cells

• Analysis approaches:

  • Mass spectrometry for unbiased protein partner identification

  • RNA-seq of associated transcripts to identify specialized translation substrates

  • Western blotting for known interactors like MDM2, p53, or other ribosomal proteins

These approaches can reveal both canonical roles in translation and non-canonical functions of RPL23.

What future developments can be anticipated in RPL23 antibody technology?

The field of RPL23 antibody development is likely to advance in several directions:

• Modification-specific antibodies targeting phosphorylated, ubiquitinated, or otherwise modified RPL23 to study regulatory mechanisms

• Single-domain antibodies (nanobodies) against RPL23 for live-cell imaging applications with minimal interference

• Bi-specific antibodies linking RPL23 with other ribosomal proteins for specialized ribosome detection

• Humanized therapeutic antibodies targeting surface-exposed RPL23 in cancer cells with dysregulated ribosome biogenesis

These developments will require extensive validation across multiple experimental systems and careful characterization of epitope specificity and accessibility in different cellular contexts.

How might computational approaches enhance RPL23 antibody research?

Integration of computational methods with RPL23 antibody research offers promising directions:

• Epitope prediction algorithms to design more specific antibodies targeting unique regions of RPL23

• Image analysis automation for quantifying subcellular distribution patterns across large datasets

• Molecular dynamics simulations predicting epitope accessibility in different RPL23 conformational states

• Network analysis of RPL23 interactome data to identify functional clusters and potential regulatory pathways

• Machine learning approaches for pattern recognition in RPL23 expression across cancer databases